- Home
- SGRY vs INBX Comparison
SGRY vs INBX Comparison
Compare SGRY & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SGRY | INBX |
|---|---|---|
| Founded | 2004 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.4B |
| IPO Year | 2015 | 2024 |
Fundamental Metrics
Financial Performance| Metric | SGRY | INBX |
|---|---|---|
| Price | $16.43 | $93.58 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 3 |
| Target Price | $22.25 | ★ $150.00 |
| AVG Volume (30 Days) | ★ 1.4M | 331.5K |
| Earning Date | 05-05-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 54.14 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,145,438,000.00 | $1,300,000.00 |
| Revenue This Year | $5.09 | N/A |
| Revenue Next Year | $5.67 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 550.00 |
| 52 Week Low | $11.41 | $20.55 |
| 52 Week High | $24.10 | $155.29 |
Technical Indicators
Market Signals| Indicator | SGRY | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 59.84 | 44.79 |
| Support Level | $15.17 | $85.94 |
| Resistance Level | $17.46 | $96.12 |
| Average True Range (ATR) | 0.64 | 7.44 |
| MACD | 0.04 | 0.78 |
| Stochastic Oscillator | 69.94 | 33.00 |
Price Performance
Historical ComparisonAbout SGRY Surgery Partners Inc.
Surgery Partners Inc is a healthcare services company with an integrated outpatient delivery model focused on providing quality, cost-effective solutions for surgical and related ancillary care in support of both patients and physicians. It has one reportable segment: Surgical Facilities, which includes the operation of ASCs, surgical hospitals, anesthesia services, and multi-specialty physician practices, which earn revenues from contracts with patients in which the performance obligations are to provide health care services.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.